Replies to post #29265 on OncoSec Medical Inc (ONCSQ)

[lasers]

david29 Medical Science persons deal with the reality of the Pharmaceutical situation and thereby bridge the politics. It is simply the case of the doers moving forward with concrete facts and realistic goals.

As a medical Science Officer of many first-time technologies I faced these situations as a consultant with many Major Pharmas. Each special situation is discussed with the technical team, a plan forged, and actions taken. Each knows their roles and moves forward accordingly.

As for $ONCS CSO Dr. Robert Pierce who was a long time key cancer researcher with Merck, his credentials are outstanding to lead $ONCS Comb P2 Melanoma with Merck's Keytruda.

A graduate of Yale College and the Brown University School of Medicine, Dr. Pierce is well regarded for his career-long research into mechanisms of immune tolerance as well as recent drug development experience, most notably being a key member of the global development team behind Merck’s FDA-designated “breakthrough” anti-PD-1 program (MK-3475). Dr. Robert H. Pierce joins OncoSec Medical from Merck Research Labs – Palo Alto (formerly DNAX Research Institute/Schering-Plough Biopharma) where he spent almost seven years leading a 20–person team, dedicated to developing disease-oriented and tissue-based translational medicine platforms. As Executive Director, Dr. Pierce was responsible for contributions to multiple successful IND applications, including critical biomarker development programs such as the anti-PD-L1 immunohistochemistry assay supporting Merck’s MK-3475 trials. In addition, Dr. Pierce was instrumental in designing two Phase 2 anti-PD-1 (MK-3475) oncology studies. Prior to focusing on immunomodulatory receptor (IMR) programs, Dr. Pierce had served as a discovery project team leader for two novel drug candidates.

From 2001 to 2007, before leaving academics to join industry, Dr. Pierce held several leadership positions at the University of Rochester School of Medicine, including Director of the Autopsy Service at Strong Memorial Hospital. From practicing as a staff pathologist to developing the graduate curriculum in pathomechamism of disease, to acting as the principal investigator of a RO1-funded research lab, Dr. Pierce played an important role in the university’s clinical and academic research programs. He continues to act as an adjunct professor at the university to this day.

He is the co-author of over fifty peer-reviewed journal articles and book chapters, and has been a reviewer for numerous scientific journals as well as National Institute of Health grants.

Dr. Pierce received his post-doctoral training at the University of Washington, Seattle, WA, his graduate education and training at Brown University School of Medicine in Providence, RI, and received his undergraduate education at Yale University in New Haven, CT. As a Fulbright Award recipient, Dr. Pierce studied Philosophy at the Albert-Ludwigs-University in Freiburg, Germany.

Dr. Pierce comments, “We stand at a transformational moment in oncology. I’m convinced that intralesional therapy with IL12 drives systemic anti-tumor immune responses and has the potential to augment immunomodulatory therapies such as anti-PD-1.”

http://oncosec.com/oncosec-medical-announces-hire-of-chief-medical-officer/

As for myself and conclusions my position is clear and remains unchanged.

Shareholders accept the true guidance of Dr. Robert Pierce and what his goals and planning are. As a medical science person I concur exactly with Dr. Pierce from the 1st day he joined $ONCS. The plan is very simple in making $ONCS Melanoma next trial a Pivotal P2B Combo with Merck's Keytruda and then apply for a Commercial BLA.

As I have stated it is absolutely unprecedented that the FDA has allowed $ONCS to proceed from a safety/tolerability P1/2A EP+IL-12 directly to an efficacy Combo P2B Keytruda + EP+IL-12.

To science medical persons this means that Dr. Pierce and the FDA have worked on an agreed Protocol for which the expected successful results in greater ORR for the Combo vs either alone will lead to Commercial BLA approval of $ONCS EP+IL-12 as an adjunct with Keytruda.